نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

Journal: :The Lancet Regional Health - Western Pacific 2023

BackgroundFirst-generation ABL-targeted tyrosine kinase inhibitor (TKI) imatinib is known to retard growth in children but it not if the second-generation TKI dasatinib has same effect. We aimed determine impact of first- or on treated for Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL).MethodsWe evaluated longitudinal changes 140 with Ph+ ALL additional inte...

Journal: :Respiratory care 2014
Herminia L Buchelli Ramirez Celso M Álvarez Álvarez José J Rodríguez Reguero Marta M García Clemente Pere Casan Clarà

Pulmonary arterial hypertension and secondary pleural effusion have been reported in association with long-term therapy with the multi-tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia. Here, we present the case of a 50-year-old man, diagnosed with chronic myeloid leukemia in August 2003, who developed pulmonary arterial hypertension after > 4 years of ...

2012
KEVIN LEDER JASMINE FOO BRIAN J. SKAGGS MERCEDES GORRE CHARLES L. SAWYERS FRANZISKA MICHOR

We perturbed the growth rate estimates for the resistant mutants by the multiplicative random factor (1 + 0.2 · U [−1, 1]) representing a 20% noise level, and performed 100 randomized trials. Table S1 shows the probability of sensitivity to imatinib (I), dasatinib (D), imatinib + dasatinib (I+D), and imatinib + dasatinib + nilotinib (I+D+N) for the baseline unperturbed growth rates, as well as ...

Journal: :Pediatric blood & cancer 2013
Diana S Osorio Jonathan L Finlay Girish Dhall Stewart Goldman David Eisenstat Robert J Brown

Germinomas and embryonal carcinomas are central nervous system (CNS) germ cell tumors (GCT) that may overexpress the proto-oncogene c-KIT, a receptor tyrosine kinase, of which dasatinib is a potent inhibitor. This retrospective review presents the feasibility and tolerability of dasatinib administration in select patients with CNS germinoma. Between November 2008 and April 2010, six patients wi...

2016
Burak Uz Ilhan Dolasik

We, herein, describe a 52-year-old male whom developed rhabdomyolysis and acute renal failure likely related to dasatinib shortly after the administration of treatment. After withdrawal of dasatinib, the myalgia reduced, and his CK returned to normal levels within a week. On follow-up acute renal failure did resolve without requiring dialysis, but unfortunately the patient died of severe respir...

Journal: :Haematologica 2007
Simona Soverini Sabrina Colarossi Alessandra Gnani Fausto Castagnetti Gianantonio Rosti Costanza Bosi Stefania Paolini Michela Rondoni Pier Paolo Piccaluga Francesca Palandri Panagiota Giannoulia Giulia Marzocchi Simona Luatti Nicoletta Testoni Ilaria Iacobucci Daniela Cilloni Giuseppe Saglio Michele Baccarani Giovanni Martinelli

The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb). In order to assess which pre-existent or emerging kinase domain mutations ar...

Journal: :Journal of Personalized Medicine 2021

Triple negative breast cancer (TNBC) is the most aggressive accounting for around 15% of identified cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, hormone independent estrogen (ER) and progesterone receptors (PR) negative, not reactive to current targeted therapies. Existing treatment relies on chemotherapeutic treatment, but in spite an initial response chemot...

2012
Peter Noy Kevin Gaston Padma-Sheela Jayaraman

The PRH/Hhex transcription factor represses multiple genes in the VEGF signalling pathway (VSP) to inhibit myeloid cell survival. Protein kinase CK2 phosphorylates PRH and counteracts the inhibitory effect of this protein on cell survival by blocking the repression of VSP genes. Here we show that the BCR-ABL/Src kinase inhibitor dasatinib decreases PRH phosphorylation and increases PRH-dependen...

2017
Ana Orive-Ramos Samuel Seoane Alberto Ocaña Atanasio Pandiella Juan Carlos Montero

Metastatic dissemination of tumor cells is responsible for the fatal outcome of breast cancer. Therefore, understanding the mechanisms involved in dissemination is essential for the development of new therapeutic strategies to prevent metastasis. One mechanism involved in metastatic dissemination of breast cancer cells is dependent on control of the production of matrix metalloproteinases by th...

Journal: :Blood 2007
Andreas Hochhaus Hagop M Kantarjian Michele Baccarani Jeffrey H Lipton Jane F Apperley Brian J Druker Thierry Facon Stuart L Goldberg Francisco Cervantes Dietger Niederwieser Richard T Silver Richard M Stone Timothy P Hughes Martin C Muller Rana Ezzeddine Athena M Countouriotis Neil P Shah

Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly problematic, and treatment options for imatinib-resistant or -intolerant CML are limited. Dasatinib, a novel, highly potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, induced cytogenetic responses in a phase 1 study in imatinib-resistant or -intole...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید